[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital do Coracao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":368},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,54,78,106,132,154,170,200,229,261,286,315,336],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":38,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100558055","national-network-for-cardiovascular-genomics-advancing-cardiovascular-healthcare-for-hereditary-diseases-in-brazils-unified-health-system-through-a-multicenter-registry-100558055",false,"NCT06546137","National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","RENOMICA-Hcor","Inclusion Criteria:\n\n* Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines\n* Agree to receive genetic counseling\n* Sign informed consent form\n* Provide the information required in the case report form\n\nExclusion Criteria:\n\n* Signature absent from informed consent form\n* Inadequate buccal swab (sample may be collected twice)","ALL",{"count":18,"type":19},1211,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:\n\nWhich genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37],"Cardiomyopathy, Hypertrophic","Cardiomyopathy, Dilated","Cardiomyopathy Restrictive","Arrhythmogenic Right Ventricular Dysplasia","Non-Compaction Cardiomyopathy","Familial Hypercholesterolemia","Marfan Syndrome","Ehlers-Danlos Syndrome, Vascular Type","Loeys-Dietz Syndrome","Long QT Syndrome","Short Qt Syndrome","Brugada Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Sudden Cardiac Death",[39,40],"hereditary cardiovascular diseases","whole genome sequencing","RECRUITING","2026-05-04",{"date":44,"type":45},"2026-05-08","ACTUAL",{"date":47,"type":45},"2025-04-30",{"date":49,"type":19},"2026-08-31",{"name":51,"class":52},"Hospital do Coracao","OTHER",27,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":65,"studyType":21,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100634013","iii-brazilian-registry-of-heart-failure-100634013","NCT07534163","III Brazilian Registry of Heart Failure","BREATHE III - THIRD PHASE OF THE BRAZILIAN HEART FAILURE REGISTRY","BREATHE III","Inclusion Criteria\n\nAdult patients (≥ 18 years) admitted to public and private hospitals with one of the two clinical conditions below:\n\n* Admission for AMI (Acute Myocardial Infarction) presenting with reduced ejection fraction during hospitalization (LVEF ≤ 40%) and which had not been previously identified (limit of 25% of the study sample included by this criterion)\n* Primary diagnosis of decompensated HF (regardless of ejection fraction), with the HF diagnosis established according to the universal definition of heart failure. In cases of HF with HFpEF, in addition to the data from the universal heart failure criteria, H2FPEF and HFA PEFF data will be collected.\n\nExclusion Criteria\n\n* Refusal to participate in the study during the informed consent process;\n* Surgical myocardial revascularization in the last month;\n* Heart failure secondary to sepsis (sepsis as the origin of heart failure);\n* Cardiogenic shock.","18 Years",{"count":64,"type":19},2000,"12 Months","BREATHE III is a prospective, multicenter, observational registry designed to provide contemporary insights into the epidemiological, clinical, and prognostic characteristics of patients hospitalized with acute heart failure (AHF) in Brazil, including those with decompensated heart failure or new-onset ventricular dysfunction during acute myocardial infarction.\n\nRecent evidence, such as the STRONG-HF trial, has demonstrated the prognostic benefit of rapid initiation and up-titration of guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF). However, prior phases of the BREATHE registry did not evaluate the timing of therapeutic optimization or barriers to implementing these strategies. Additionally, the therapeutic landscape of heart failure has evolved substantially in recent years, with the introduction of novel pharmacological agents, expanded indications for existing therapies, and new treatment options for heart failure with preserved ejection fraction (HFpEF).\n\nBREATHE III aims to address these knowledge gaps by systematically assessing, over a 12-month follow-up, patient characteristics, treatment patterns, adherence to guideline-recommended therapies, time to treatment optimization, and clinical outcomes. The study will also identify barriers to the implementation and titration of evidence-based therapies, evaluate regional variations in care, and describe contemporary management practices across public and private healthcare settings in Brazil.\n\nThe results of this registry are expected to inform strategies to improve quality of care, optimize resource allocation, and guide future interventions aimed at reducing morbidity and mortality associated with heart failure in Brazil.",[68],"Heart Failure","NOT_YET_RECRUITING","2026-04-15",{"date":72,"type":45},"2026-04-16",{"date":74,"type":19},"2026-04-20",{"date":76,"type":19},"2028-10-01",{"name":51,"class":52},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100630835","hypofractionated-radiotherapy-plus-temozolamide-in-patients-younger-than-70-years-with-glioblastoma-100630835","NCT07492836","Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma","Prospective, Pilot Study to Evaluate Hypofractionated Radiotherapy Associated With Temozolomide in Patients Aged 18 to 70 Years With Glioblastoma (HypoGBM)","HipoGBM","Inclusion Criteria:\n\n* Initial histological diagnosis of glioblastoma\n* Age \\> 18 and \\\u003C 70 years;\n* Karnofsky Performance Status \\> 70%;\n* Patient consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients submitted to any type of previous radiotherapy in the cranial region;\n* Multicentric tumors;\n* Contraindication to chemotherapy with temozolomide;\n* Contraindications for performing magnetic resonance imaging (MRI), such as the use of implants or metallic prostheses;\n* Pregnant women or women of childbearing age who refuse to undergo the beta-HCG test before treatment and contraception during the intervention.","70 Years",{"count":88,"type":19},10,"INTERVENTIONAL",[91],"NA","The goal of this clinical trial is to evaluate the feasibility, safety and effectiveness of radiotherapy with fewer days of treatment and a higher dose of radiation each day in patients under 70 years of age diagnosed with a brain tumor known as glioblastoma.",[94],"Glioblastoma (GBM)",[96,97],"Radiotherapy","Temozolamide","2026-03-19",{"date":100,"type":45},"2026-03-25",{"date":102,"type":19},"2026-04",{"date":104,"type":19},"2029-04",{"name":51,"class":52},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":89,"phases":115,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100617887","one-hour-positive-pressure-ventilation-after-a-pressure-support-spontaneous-breathing-trial-100617887","NCT07324460","One-Hour Positive Pressure Ventilation After a Pressure Support Spontaneous Breathing Trial","One-Hour Positive Pressure Ventilation After a Pressure Support Spontaneous Breathing Trial: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients aged \\> 18 years.\n* Admitted to the intensive care unit (surgical or medical).\n* With endotracheal intubation.\n* Mechanical ventilation for more than 72 hours.\n* Who underwent successful spontaneous breathing trial (according to the study protocol) and is considered able to be extubated.\n\nExclusion Criteria:\n\n* Patients unable to obey commands.\n* With non-planned extubation.\n* Neuromuscular disease and cervical spinal cord injury.\n* Tracheostomy.\n* Contraindication for cardiopulmonary resuscitation or reintubation.\n* Terminal extubation.\n* Lack of informed consent.\n* Previously included in the trial.",{"count":114,"type":19},4000,[91],"This is a randomized, open, multicenter, pragmatic, adaptive clinical trial with intention-to-treat analysis. The study will compare two weaning strategies from mechanical ventilation in critically ill patients admitted to intensive care units, with more than 72 hours of mechanical ventilation and with a successful spontaneous breathing trial on pressure support. Immediately after a successful spontaneous breathing trial, eligible patients will be randomized into 2 groups that will be treated according to one of the following interventions:1) One-hour positive pressure ventilation: as soon as the success of the spontaneous breathing trial is confirmed, the patient is submitted to mechanical ventilation for 1 hour using the previous ventilatory parameters and, afterwards, extubated.2) Immediate extubation: the patient is extubated immediately after the success of the spontaneous breathing trial.",[118,119,120],"Airway Extubation","Weaning Mechanical Ventilation","Extubation Failure",[122,119,123],"Airway extubation","Extubation failure","2026-02-11",{"date":126,"type":45},"2026-02-12",{"date":128,"type":19},"2026-02",{"date":130,"type":19},"2030-02",{"name":51,"class":52},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100618883","characterization-of-weaning-practices-in-icus-of-global-south-countries-100618883","NCT07337408","Characterization of Weaning Practices in ICUs of Global South Countries","Characterization of Weaning Practices in ICUs of Global South Countries: A Prospective Observational Study","Inclusion Criteria:\n\n* Age \\> 18 years.\n* Receiving care at an intensive care unit.\n* Endotracheal intubation.\n* Mechanical ventilation for 12 hours or more.\n* First separation attempt, as defined in the WIND Classification - \"Separation attempt from mechanical ventilation: an spontaneous breathing trial with or without extubation, or an extubation directly performed without identified spontaneous breathing trial (whatever the type: planned or unplanned extubation)\" - planned to occur in the next 6 hours or that occurred less than 2 hours ago.\n\nExclusion Criteria:\n\n* Patients with prior extubation failure.\n* Patients with prior spontaneous breathing trial failure.\n* Patients unable to obey commands.\n* Neuromuscular disease or cervical spinal cord injury.\n* Tracheostomy.\n* Do-not-resuscitate order or contraindication for reintubation.\n* Lack of informed consent.\n* Terminal extubation.\n* Previously included in the study.",{"count":140,"type":19},900,"This is a prospective observational study to be conducted in intensive care units of Global South countries. Patients on mechanical ventilation for more than 12 hours who have initiated the weaning process and for whom the attending team plans extubation within the next 6 hours will be included. Data will be collected for each patient during the first 7 days after extubation, with follow-up until hospital discharge or death. We plan to conduct the study in intensive care units from Global South countries (low- and middle-income countries predominantly located in the Southern Hemisphere, though some in the Northern Hemisphere are also considered).",[143,144,145],"Weaning From Mechanical Ventilation","Weaning Failure","Weaning From Mechanical Ventilation, Extubation",[147,144,148],"Weaning from mechanical ventilation","Weaning from mechanical ventilation, extubation",{"date":126,"type":45},{"date":128,"type":19},{"date":152,"type":19},"2027-04",{"name":51,"class":52},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":89,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":168,"leadSponsor":169,"locationsCount":4},"100617881","one-hour-positive-pressure-ventilation-after-a-t-piece-spontaneous-breathing-trial-100617881","NCT07324382","One-Hour Positive Pressure Ventilation After a T-Piece Spontaneous Breathing Trial","One-Hour Positive Pressure Ventilation After a T-Piece Spontaneous Breathing Trial: A Randomized Clinical Trial","GS-Wean Tpiece",{"count":114,"type":19},[91],"This is a randomized, open, multicenter, pragmatic, adaptive clinical trial with intention-to-treat analysis. The study will compare two weaning strategies from mechanical ventilation in critically ill patients admitted to intensive care units, with more than 72 hours of mechanical ventilation and with a successful spontaneous breathing trial on T-piece. Immediately after a successful spontaneous breathing trial, eligible patients will be randomized into 2 groups that will be treated according to one of the following interventions:\n\n1. One-hour positive pressure ventilation: as soon as the success of the spontaneous breathing trial is confirmed, the patient is submitted to mechanical ventilation for 1 hour using the previous ventilatory parameters and, afterwards, extubated.\n2. Immediate extubation: the patient is extubated immediately after the success of the spontaneous breathing trial.",[118,120,119],[122,123,119],{"date":126,"type":45},{"date":128,"type":19},{"date":130,"type":19},{"name":51,"class":52},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":89,"phases":180,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},"100551778","phase-3-norepinephrine-and-vasopressin-for-rescue-versus-early-vasopressin-for-vasopressor-dependent-sepsis-100551778","NCT06464510","Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis","Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis: An Open-label, Multicenter, Randomized, Controlled Trial: NoVa","NoVa","Inclusion Criteria:\n\n* Patients with vasopressor dependent sepsis, defined by infection suspicion and antibiotic administration or laboratory confirmed viral infection, plus hypotension with the need of vasopressors for at least one hour;\n* Admitted or expected to be admitted to the ICU in the next 12 hours\n* Adequate volume resuscitation in the opinion of the attending physician\n* Use of norepinephrine \\> 0.05μg\u002FKg\u002Fmin and ≤ 0.25μg\u002FKg\u002Fmin for at least 1 hour and at most 24 hours at the time of inclusion\n\nExclusion Criteria:\n\n* Use of norepinephrine \\> 0.25μg\u002FKg\u002Fmin in the last 24 hours, except when administered transiently in the context of sedation for a procedure or the initial phase of volume resuscitation for a period of less than one hour\n* Dialysis-dependent chronic kidney disease or acute kidney injury that received renal replacement therapy during current hospitalization or are expected to receive renal replacement therapy in the next 24 hours\n* Use of other vasopressors (except norepinephrine) at the moment of inclusion\n* Use of vasopressors for sepsis in the last 7 days\n* Suspected or confirmed acute mesenteric ischemia\n* Anaphylaxis or known hypersensitivity to the study drug\n* Expect to die in the next 24 hours\n* Medical team not committed to full support at the time of inclusion\n* Previous inclusion in the study",{"count":179,"type":19},2800,[181],"PHASE3","The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.",[184],"Septic Shock",[186,187,188,189,190],"Vasopressin","Norepinephrine","Vasopressor dependent sepsis","Septic shock","Critically ill","2026-01-28",{"date":193,"type":45},"2026-01-30",{"date":195,"type":45},"2024-11-21",{"date":197,"type":19},"2027-09",{"name":51,"class":52},8,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":89,"phases":211,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":5},"100587630","phase-3-polypill-and-colchicine-for-risk-reduction-in-atherosclerotic-cardiovascular-disease-100587630","NCT06930885","Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","Evaluation of a POlypill and Colchicine for Risk Reduction in Patients With Established Atherosclerotic Cardiovascular Disease: The EPOCA Randomized Clinical Trial","EPOCA","Inclusion Criteria:\n\n* Individuals aged ≥ 45 years AND\n* Signature of the Informed Consent Form (ICF) AND at least one of the following criteria:\n* Previous atherothrombotic cardiovascular event (acute coronary syndrome, ischemic stroke, high-risk transient ischemic stroke, acute limb ischemia\u002Farterial occlusion, or non-traumatic limb amputation) AND\u002FOR\n* Previous arterial revascularization (percutaneous, surgical, and\u002For hybrid) OR\n* Diagnosis of significant atherosclerotic disease with ≥ 50% obstruction in any arterial territory (coronary, cerebrovascular, or peripheral), in the absence of a prior cardiovascular event or arterial revascularization.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Women of childbearing age who do not use any form of contraception;\n* Known history of chronic kidney disease, stage ≥ 4 (estimated glomerular filtration rate ≤ 30 mL\u002Fmin, if available);\n* Known history of cirrhosis or severe liver disease (e.g., transaminase levels \\> 3 times the upper limit of normal, if available);\n* Known history of inflammatory muscle disease (e.g., dermatomyositis or polymyositis) or creatine phosphokinase (CPK) levels \\> 3 times the upper limit of normal, if available);\n* Known history of moderate or severe valvular heart disease with anticipated need for valvular intervention within the next 12 months;\n* Planned arterial revascularization (inclusion is possible 30 days after completion of all planned procedures);\n* Left ventricular ejection fraction ≤40% (with the exception of patients with documented intolerance to ACE inhibitors and\u002For sacubitril\u002Fvalsartan, who remain eligible for study enrollment);\n* Heart failure with functional class ≥ III according to the New York Heart Association (NYHA), regardless of left ventricular ejection fraction;\n* Blood pressure \\\u003C 120\u002F80 mmHg in the absence of antihypertensive therapy;\n* Life expectancy ≤ 12 months;\n* Acute arterial event (acute coronary syndrome, non-cardioembolic ischemic stroke, acute limb ischemia) in the past 30 days;\n* Substance abuse\u002Falcoholism;\n* Psychiatric and\u002For neurodegenerative disorder limiting self-care capacity;\n* Concurrent participation in another randomized clinical trial;\n* Contraindication to any component of the polypill;\n* Current or planned use of oral anticoagulant therapy within the next 12 months (except rivaroxaban 2.5 mg twice daily for patients with peripheral artery disease);\n* High risk of bleeding (e.g., but not limited to: blood dyscrasias, hemophilia, previous gastrointestinal or central nervous system bleeding);\n* Contraindication to colchicine;\n* Current use of colchicine.","45 Years",{"count":210,"type":19},7713,[181],"The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.",[214,215],"Atherothrombotic Diseases","Atherosclerotic Cardiovascular Disease (ASCVD)",[217,218,219,220],"Atherothrombotic diseases","Atherosclerotic cardiovascular disease","Polypill","Colchicine","2026-01-21",{"date":223,"type":45},"2026-01-22",{"date":225,"type":45},"2025-06-12",{"date":227,"type":19},"2031-05",{"name":51,"class":52},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":89,"phases":239,"briefSummary":240,"conditions":241,"keywords":247,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},"100602916","oral-care-layered-enhancement-for-improved-oral-hygiene-in-intensive-care-units-100602916","NCT07129733","Oral Care Layered Enhancement for Improved Oral Hygiene in Intensive Care Units","Oral Care Layered Enhancement for Improved Oral Hygiene in Intensive Care Units: A Stepped-Wedge Cluster Randomized Clinical Trial","ORACLE","Inclusion Criteria:\n\n* All patients who receive mechanical ventilation in the participating intensive care units\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria",{"count":238,"type":19},4800,[91],"The goal of the ORACLE study is to evaluate the impact of implementing a standardized oral hygiene bundle on outcomes in critically ill, mechanically ventilated patients. The primary objective is to determine whether this bundle can increase the number of ventilator-free days compared to the standard of care.",[242,243,244,245,246],"Mechanical Ventilation","Infection Prevention","Oral Care","Oral Hygiene, Oral Health","VAP - Ventilator Associated Pneumonia",[248,249,250,251],"Oral care","Oral hygiene","critically ill","mechanical ventilation","2025-08-15",{"date":254,"type":45},"2025-08-19",{"date":256,"type":19},"2025-09-01",{"date":258,"type":19},"2026-11-30",{"name":51,"class":52},6,{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":89,"phases":270,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":285},"100595828","phase-1-low-dose-radiotherapy-for-heart-failure-100595828","NCT07037524","Low Dose Radiotherapy for Heart Failure","Prospective Pilot Single-center Study to Evaluate the Safety and Efficacy of Low-dose Radiotherapy in Patients With Heart Failure","RadioCardio","Inclusion Criteria\n\n* Age \\>18 years;\n* Clinical and laboratory diagnosis of chronic systolic HF grades II or III of the New York Heart Association with ejection fraction \\\u003C40%;\n* Refractoriness to standard clinical treatment; defined as the persistence of HF signs and symptoms despite optimized drug therapy.\n* Patient consent to participate in the study.\n* Agreement to adopt contraceptive practices\u002Fmethods until the end of the intervention for women of childbearing age.\n\nExclusion Criteria\n\n* Patients who have undergone any type of previous radiotherapy in the thoracic region;\n* Patients who have undergone heart transplants;\n* Contraindications for magnetic resonance imaging (MRI), such as the use of metal implants or prostheses.\n* Pregnant patients.",{"count":88,"type":19},[271,272],"PHASE1","PHASE2","The primary goals of this clinical trial are to evaluate the safety and efficacy of a low dose whole-heart radiotherapy with a single fraction in ten participants with advanced heart failure.",[275],"Heart Failure - NYHA II - IV",[68,96],"2025-06-24",{"date":279,"type":45},"2025-06-25",{"date":281,"type":19},"2025-07-14",{"date":283,"type":19},"2030-09-30",{"name":51,"class":52},1,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":89,"phases":296,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":314},"100580569","phase-3-cryoablation-for-small-tumors-as-local-treatment---six-trial-100580569","NCT06839001","CRYoablation for Small Tumors As Local Treatment - SIX Trial","Cryoablation Versus Breast Surgery in the Local Treatment of Early-Stage Breast Cancer - Six Trial","CRYSTAL - SIX","Inclusion Criteria:\n\n* Unifocal primary invasive breast carcinoma\n* Tumor size ≤ 2.0 cm (T1)\n* Complete pathological report (including results for ER, PR, HER2, Ki-67, and FISH report for the ERBB2 gene, if necessary)\n* Lesion visible on ultrasound\n* Surgical treatment would be the first option, regardless of immunohistochemistry results\n\nExclusion Criteria:\n\n* Multifocal or multicentric invasive breast carcinoma\n* Ductal carcinoma in situ\n* Breast cancer with skin involvement\n* Clinically positive axilla (N1, N2 or N3)\n* Distance from lesion and skin less than 5 mm\n* Prior neoadjuvant systemic therapy for breast cancer\n* Distant metastasis",{"count":295,"type":19},750,[181],"To demonstrate the non-inferiority of cryoablation compared to breast surgery for the local treatment of early-stage breast cancer and to conduct a cost-minimization analysis comparing direct costs between treatments.",[299,300],"Breast Cancer","Breast Neoplasm",[299,302,303,304,305],"Minimally Invasive Surgical Procedures","Cryoablation","Locoregional Recurrence","Cost-Minimization Analysis","2025-06-23",{"date":308,"type":45},"2025-06-26",{"date":310,"type":45},"2025-03-01",{"date":312,"type":19},"2030-03-01",{"name":51,"class":52},2,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":89,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":333,"leadSponsor":335,"locationsCount":285},"100558190","phase-2-use-of-vasopressin-in-patients-at-high-risk-of-acute-kidney-injury-admitted-to-the-icu-100558190","NCT06547892","Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU","Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU: a Feasibility Randomized Clinical Trial","NOVA-AKI","Inclusion Criteria:\n\n* Adult patients (≥18 years old);\n* Admitted to intensive care units;\n* Predicted risk of acute kidney injury calculated based on clinical and laboratory data at ICU admission and is considered eligible if the value in the calculator is equal or greater than 5 points;\n\nExclusion Criteria:\n\n* Time since admission to the ICU greater than 24 hours;\n* Use of vasopressors at the time of inclusion;\n* MAP \\>90 mmHg;\n* Hyponatremia (\\\u003C130 mmol\u002FL);\n* Severe TBI with Glasgow Coma Scale \\\u003C 8;\n* Elective surgeries;\n* Dialysis chronic kidney disease or acute kidney injury who received renal replacement therapy upon admission or are expected to receive renal replacement therapy within the next 24 hours;\n* Suspected or confirmed acute mesenteric ischemia;\n* Prospect of death in less than 24 hours;\n* Medical team not committed to full investment at the time of inclusion;\n* Prior inclusion in the study;\n* Pregnancy.",{"count":324,"type":19},60,[272],"Renal dysfunction is a frequent complication in patients admitted to intensive care units (ICUs), associated with high morbidity and mortality. Current therapeutic options to prevent this condition are limited and lack robust scientific evidence. This pilot study consists of a multicenter, blinded, randomized clinical trial, unprecedented in the literature to date, aiming to fill this knowledge gap and offer new therapeutic perspectives to improve renal outcomes in critically ill patients admitted to the ICU.",[328],"Critical Illness","2025-04-10",{"date":331,"type":45},"2025-04-13",{"date":329,"type":45},{"date":334,"type":19},"2025-12-10",{"name":51,"class":52},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":344,"minAge":62,"maxAge":86,"enrollmentInfo":345,"targetDuration":4,"studyType":89,"phases":347,"briefSummary":348,"conditions":349,"keywords":353,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":367},"100497960","phase-3-adjuvant-chemotherapy-in-cfhpv-dna-plasma-positive-patients-a-biomarker-in-locally-advanced-cervical-cancer-100497960","NCT05764044","Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer","Adjuvant Chemotherapy in Cell-free Human Papillomavirus Deoxyribonucleic Acid (cfHPV-DNA) Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer (CC)","AddChemo","Inclusion Criteria:\n\n* International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3 to IVA will be included prospectively.\n* Previous standard treatment based on concomitant chemoradiotherapy regimen.\n* Karnofsky performance status score ≥70, with estimated life expectancy ≥12 weeks,\n* Immunocompetent,\n* Positive research for types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82 cfHPV-DNA in plasma at the end of chemoradiotherapy,\n* Proper hematological, liver and kidney functions. Inclusion criteria will include absolute neutrophils count ≥1.5 x 109\u002FL, platelets ≥100 x 10\u002FL, serum bilirubin ≤ 2.0 x upper limit of normal (ULN), calculated creatinine clearance ≥50 mL\u002Fmin and alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase ≤ 2.5 x ULN.\n* Patients of child-bearing potential were obligated to use an approved contraceptive method during and for 3 months after the study;\n* Agree with research procedures, by signing the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Previous cervical cancer or other malignancies,\n* Pregnant women,\n* Inability to perform concurrent cisplatin based-chemoradiotherapy.\n* Tumors containing different HPV genotypes\n* Absence of anatomopathological examination to prove the diagnosis and\u002For staging examinations.","FEMALE",{"count":346,"type":19},365,[181],"This study hypothesizes that patients who persist with cell-free human papillomavirus deoxyribonucleic acid (cfHPV-DNA) plasma expression at the end of standard treatment, can derive the benefit of using adjuvant chemotherapy in locally advanced cervical cancer (CC). After standard treatment based on concomitant chemoradiotherapy regime, a qualitative and quantitative research of cfHPV-DNA in plasma of patients will be conducted. Patients who have positive research for plasma cfHPV-DNA at the end of chemoradiotherapy treatment will be randomized to receive two additional cycles of adjuvant chemotherapy or observation. Patients will be followed with conduction of computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.",[350,351,352],"Cervical Cancer","Cervix Cancer","Cervix Neoplasm",[354,355,356,357,358],"Human papillomavirus","HPV","Cervical cancer","Circulating free DNA","Adjuvant chemotherapy","2024-07-28",{"date":361,"type":45},"2024-07-30",{"date":363,"type":45},"2024-03-27",{"date":365,"type":19},"2026-12-31",{"name":51,"class":52},26,""]